News

Buyback Alert: Shareholders of this ₹1,400 crore drugmaker approve repurchase plan; Check premiumJagsonpal Pharma will share the timelines and record date of the proposed buyback in due course.By Shloka Badkar   April 27, 2026, 9:13:23 AM IST (Published)1 Min ReadShares of Jagsonpal Pharmaceuticals Ltd. gained up to 2% on Monday, April 27, after the company received shareholders' approval for its buyback proposal.

On March 12, 2026, the company's board had proposed the buyback of up to 16 lakh equity shares at ₹250 per equity share worth around ₹40 crore. On March 11, the stock had closed at ₹179.24, which meant that the buyback was at a premium of nearly 40% from its previous day's closing price.

Based on the stock's closing price on Friday, the buyback price is now at a 26% premium.

The proposal was subject to shareholder approval, the results of which were announced on Monday, April 27.

Jagsonpal Pharma will share the timelines and record date of the proposed buyback in due course.

It said the buyback is aligned with the company's broader strategy of balancing growth investments with shareholder returns.

At the end of the March quarter, the promoter and promoter group held 67.89% stake in the company, while the public shareholding was at 32.11%

Shares of Jagsonpal Pharma are up 2% in early trading on Monday at ₹203.17. The stock has risen 10% so far in the last one month.

Also Read: Reliance Industries' highest share price target implies a 44% upside; Here are key triggers

 Continue ReadingTagsbuybackshare market today